Alisertib Induces Early Signals of Efficacy in Endocrine-Resistant Breast Cancer
Alisertib as monotherapy and in combination with fulvestrant stands at the forefront of the clinical investigation of selective AURKA pathway inhibition in patients with endocrine-resistant advanced breast cancer, according to Tufia C. Haddad, MD.
Source: onclive.com